HCW Biologics Doses First Patient in Alopecia Areata Trial with HCW9302

HCW Biologics has dosed the first patient in a multi-center clinical trial for HCW9302, an immunotherapeutic targeting chronic inflammation. The trial evaluates HCW9302 in patients with alopecia areata and involves The Ohio State University Wexner Medical Center. HCW9302 is an interleukin-2-based treatment designed to regulate excessive inflammation and control autoimmune diseases.